

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
21 February 2002 (21.02.2002)

PCT

(10) International Publication Number
WO 02/13821 A1(51) International Patent Classification⁷: **A61K 31/4164**,
C07D 233/64(74) Agents: **KATZ, Martin, L.** et al.; Rockey, Milnamow &
Katz, Ltd., Suite 4700, Two Prudential Plaza, 180 N. Stet-
son Ave., Chicago, IL 60601 (US).(21) International Application Number: **PCT/US01/41738**(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW.

(22) International Filing Date: 15 August 2001 (15.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/225,968 17 August 2000 (17.08.2000) US(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).(71) Applicant (*for all designated States except US*): **GLIAT-
ECH, INC.** [US/US]; 23420 Commerce Road, Cleveland,
OH 44122 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **RONG, Yajing**
[CN/US]; Apt #616, 27020 Cedar Road, Beachwood, OH
44122 (US). **JIANG, Jack, B.** [—/US]; 455 Nob Hill
Oval, Orange Village, OH 44022 (US). **ALI, Syed, M.**
[IN/US]; 34463 Clayton Drive, Solon, OH 44139 (US).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

WO 02/13821 A1

(54) Title: NOVEL ALICYCLIC IMIDAZOLES AS H₃ AGENTS(57) Abstract: Alicyclic imidazole compounds; pharmaceutically active compositions containing such compounds; and the use of such compounds in formulations for the control or prevention of disease states in which histamine H₃ receptors are involved, such as allergy, inflammation, hypotension, glaucoma, sleeping disorders, states of hyper- and hypo-motility of the gastro-intestinal tract, cardiovascular disease, hypo- and hyper-activity of the central nervous system, Alzheimer's, schizophrenia, obesity and migraines are disclosed.

WO 02/13821

PCT/US01/41738

1

NOVEL ALICYCLIC IMIDAZOLES AS H₃ AGENTS

5

Field of the Invention

The present invention is directed to alicyclic imidazoles which interact with the histamine H₃ receptor as agonists, antagonists or inverse agonists; pharmaceutically active compositions containing such compounds; and the use of such compounds in formulations for the control or prevention of disease states in which histamine H₃ receptors are involved, such as allergy, inflammation, hypotension, glaucoma, sleeping disorders, states of hyper- and hypo-motility of the gastro-intestinal tract, cardiovascular disease, hypo- and hyper-activity of the central nervous system, Alzheimer's, schizophrenia, obesity and migraines.

15

Background of the Invention

Histamine plays a role in regulating attentiveness and cognition in the central nervous system (CNS), and histamine levels in the brain are controlled by the histamine H₃ receptor. Moreover, serotonin, norepinephrine, dopamine and acetylcholine all have been demonstrated to be regulated by the histamine H₃ receptor. These neurotransmitters are known to play a role in many CNS psychiatric disorders involving higher cognitive function and/or emotion. Consequently, compounds affecting H₃ receptor function (as agonists, antagonists or inverse agonists) could have utility in the treatment of a variety of CNS maladies, including but not limited to dementias, attention deficit hyperactivity disorder, depression, anxiety and schizophrenia.

20

25

30

Histamine is also involved in the control of sleep/wake states and appetite. Accordingly, histamine H₃ receptor ligands might be expected to be useful in treating insomnia, narcolepsy, age-related sleep disorders, obesity and anorexia. Although they exist in low density outside of the brain, histamine H₃ receptors are found on the sympathetic and parasympathetic nerve terminals in

WO 02/13821

PCT/US01/41738

2


the periphery, including the vasculature and heart. Thus, compounds that alter histamine H₃ receptor activity might also have clinical utility in treating conditions such as migraine and cardiac dysfunction.

Various imidazole-containing compounds are disclosed in WO 92/15567, WO 93/12107, and U.S. Patent Nos. 5,217,986 and 5,559,113. 2-(4-imidazolyl) cyclopropylamine is disclosed in U.S. Patent No. 4,767,778. 1H-4(5)-substituted imidazole derivatives are disclosed in WO 96/38142 and U.S. Patent No. 6,072,057. 2-(1H-4(5)-imidazolyl) cyclopropyl derivatives are disclosed in U.S. Patent Nos. 6,008,240; 5,990,317 and 5,652,258. However, there is still a need for novel, histamine H₃ receptor-active imidazolyl cyclopropyl derivatives.

Brief Summary of the Invention

The present invention is directed to alicyclic imidazoles which interact with the histamine H₃ receptor as agonists, antagonists or inverse agonists; pharmaceutically active compositions containing such compounds; and the use of such compounds in formulations for the control or prevention of disease states in which histamine H₃ receptors are involved, such as allergy, inflammation, hypotension, glaucoma, sleeping disorders, states of hyper- and hypo-motility of the gastro-intestinal tract, cardiovascular disease, hypo- and hyper-activity of the central nervous system, Alzheimer's, schizophrenia, obesity and migraines.

The invention is directed to novel compounds of Formula I as follows:



Formula I

wherein n is an integer of zero to six;
p is an integer of zero to two;
q is an integer of zero to four;

WO 02/13821

PCT/US01/41738

3

- 5 T is selected from the group consisting of $-\text{NR}^6\text{R}^7$, $-\text{N}(\text{R}^8)\text{C}(\text{NR}^9)\text{R}^{10}$,
 $-\text{CN}$, $-\text{OH}$, $-\text{H}$, $-\text{OR}^{11}$, $-\text{OC}(\text{O})\text{R}^{12}$, $-\text{C}(\text{O})\text{R}^{13}$, $-\text{C}(\text{O})\text{NH}_2$, $-\text{C}(\text{N}-$
 $\text{OH})\text{H}$, $-\text{SC}(\text{S})\text{R}^{14}$, $-\text{NR}^{15}\text{C}(\text{S})\text{R}^{16}$, $-\text{NR}^{17}\text{C}(\text{O})\text{R}^{18}$, $-\text{SC}(\text{NR}^{19})\text{R}^{20}$,
 $-\text{OC}(\text{NR}^{21})\text{R}^{22}$, R^{23} , $-\text{N}(\text{R}^{24})\text{C}(\text{O})\text{N}(\text{R}^{25})$, $-\text{N}(\text{R}^{26})\text{C}(\text{O})$, and
 $-\text{O}(\text{O})\text{NR}^{27}\text{R}^{28}$;
- 10 R^1 is selected from the group consisting of hydrogen, hydroxyl, alkyl,
alkenyl, alkynyl, alkoxy, alkenoxy, alkynoxy, thioalkoxy,
hydroxyalkyl, aliphatic acyl, $-\text{CF}_3$, $-\text{N}(\text{C}_1\text{-C}_3 \text{ alkyl})\text{-C}(\text{O})(\text{C}_1\text{-C}_3$
alkyl), $-\text{NHC}(\text{O})\text{NH}(\text{C}_1\text{-C}_3 \text{ alkyl})$, $-\text{NHC}(\text{O})\text{N}(\text{C}_1\text{-C}_3$
15 alkyl) $\text{C}(\text{O})\text{NH}(\text{C}_1\text{-C}_3 \text{ alkyl})$, $-\text{C}_1\text{-C}_3$ alkylamino, alkenylamino,
alkynylamino, $\text{di}(\text{C}_1\text{-C}_3 \text{ alkyl})\text{amino}$, $-\text{C}(\text{O})\text{O}-(\text{C}_1\text{-C}_3 \text{ alkyl})$, $-\text{C}(\text{O})\text{NH}-(\text{C}_1\text{-C}_3 \text{ alkyl})$, $-\text{CH}=\text{NOH}$, $-\text{PO}_3\text{H}_2$, $-\text{OPO}_3\text{H}_2$, $-\text{C}(\text{O})\text{N}(\text{C}_1\text{-C}_3 \text{ alkyl})_2$, haloalkyl, alkoxyalkoxy, carboxaldehyde,
carboxamide, cycloalkyl, cycloalkenyl, cycloalkynyl,
20 cycloalkylalkyl, aryl, aroyl, aryloxy, arylamino, biaryl, thioaryl,
diarylamino, heterocyclyl, alkylaryl, aralkenyl, aralkyl,
alkylheterocyclyl, heterocyclylalkyl, sulfonyl, $-\text{SO}_2-(\text{C}_1\text{-C}_3$
alkyl), $-\text{SO}_3-(\text{C}_1\text{-C}_3 \text{ alkyl})$, sulfonamido, aryloxyalkyl, carboxyl,
carbamate and $-\text{C}(\text{O})\text{NH}(\text{benzyl})$; and
- 25 $\text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{11}, \text{R}^{12}, \text{R}^{13}, \text{R}^{14}, \text{R}^{15}, \text{R}^{16}, \text{R}^{17}, \text{R}^{18}, \text{R}^{19},$
 $\text{R}^{20}, \text{R}^{21}, \text{R}^{22}, \text{R}^{23}, \text{R}^{24}, \text{R}^{25}, \text{R}^{26}, \text{R}^{27}$ and R^{28}
are each independently selected from the group consisting of
hydrogen, halogen, hydroxyl, alkyl, alkenyl, alkynyl, alkoxy,
alkenoxo, alkynoxo, thioalkoxy, hydroxyalkyl, aliphatic acyl, $-\text{CF}_3$, $-\text{NO}_2$, amino, $-\text{CN}$, carboxy, $-\text{N}(\text{C}_1\text{-C}_3 \text{ alkyl})\text{-C}(\text{O})(\text{C}_1\text{-C}_3$
25 alkyl), $-\text{NHC}(\text{O})\text{NH}(\text{C}_1\text{-C}_3 \text{ alkyl})$,
 $-\text{NHC}(\text{O})\text{N}(\text{C}_1\text{-C}_3 \text{ alkyl})\text{C}(\text{O})\text{NH}(\text{C}_1\text{-C}_3 \text{ alkyl})$, $-\text{C}_1\text{-C}_3$
alkylamino, alkenylamino, alkynylamino, $\text{di}(\text{C}_1\text{-C}_3 \text{ alkyl})\text{amino}$,
 $-\text{C}(\text{O})\text{O}-(\text{C}_1\text{-C}_3 \text{ alkyl})$, $-\text{C}(\text{O})\text{NH}-(\text{C}_1\text{-C}_3 \text{ alkyl})$, $-\text{CH}=\text{NOH}$,
30 $-\text{PO}_3\text{H}_2$, $-\text{OPO}_3\text{H}_2$, $-\text{C}(\text{O})\text{N}(\text{C}_1\text{-C}_3 \text{ alkyl})_2$, haloalkyl,
alkoxyalkoxy, carboxaldehyde, carboxamide, cycloalkyl,
cycloalkenyl, cycloalkynyl, cycloalkylalkyl, aryl, aroyl, aryloxy,

WO 02/13821

PCT/US01/41738


4

- arylamino, biaryl, thioaryl, diarylamino, heterocyclyl, alkylaryl, aralkenyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, sulfonyl, -SO₂-(C₁-C₃ alkyl), -SO₃-(C₁-C₃ alkyl), sulfonamido, aryloxyalkyl, carboxyl, carbamate and -C(O)NH(benzyl);
- 5 wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²⁰, R²¹, R²², R²³, R²⁴, R²⁵, R²⁶, R²⁷ and R²⁸ are unsubstituted or substituted with at least one electron donating or electron withdrawing group; and pharmaceutically acceptable salts thereof;
- 10 with the proviso that when T is -NR⁶R⁷, R¹ is hydrogen and n is zero, R⁶ and R⁷ are not both hydrogen; and the proviso that when T is -OH, n is one, R⁴ and R⁵ are each hydrogen, and p and q are zero, R¹ is not triphenylmethyl; and the proviso that when T is -C(O)R¹³ and n is zero, R¹³ is not
- 15 hydrogen or a chiral moiety.

For compounds of Formula I, n may be an integer of zero to three; R¹ may be hydrogen, R², R³, R⁴ and R⁵ may each independently be hydrogen, halogen, hydroxyl, lower alkyl, alkenyl, alkynyl or aryl; and R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²⁰, R²¹, R²² and R²³ may each be

20 hydrogen, lower alkyl, alkenyl, alkynyl, aryl and heterocyclyl. Presently preferred compounds of Formula I have T as -N(R⁸)C(NR⁹)R¹⁰, -OC(O)R¹², -C(O)R¹³, -C(O)NH₂, -C(N-OH)H, -SC(S)R¹⁴, -NR¹⁵C(S)R¹⁶, -NR¹⁷C(O)R¹⁸, -SC(NR¹⁹)R²⁰ or -OC(NR²¹)R²² when n is zero or T as -NR⁶R⁷, -CN, -OH, -H, -OR¹¹ or R²³ when n is one.

25 More specifically, the compounds of this invention may be described by Formula II below



Formula II

WO 02/13821

PCT/US01/41738

5

wherein n is an integer of zero to three;

T is selected from the group consisting of $-NR^6R^7$, $-N(R^8)C(NR^9)R^{10}$,
 $-CN$, $-OH$, $-H$, $-OR^{11}$, $-OC(O)R^{12}$, $-C(O)R^{13}$, $-C(O)NH_2$, $-C(N-$
 $OH)H$, $-SC(S)R^{14}$, $-NR^{15}C(S)R^{16}$, $-NR^{17}C(O)R^{18}$, $-SC(NR^{19})R^{20}$,
 $-OC(NR^{21})R^{22}$ and R^{23} ;

R^1 is selected from the group consisting of hydrogen, hydroxyl, alkyl,
 alkenyl, alkynyl, alkoxy, alkenoxy, alkynoxy; thioalkoxy,
 hydroxyalkyl, aliphatic acyl, $-CF_3$, $-N(C_1-C_3 \text{ alkyl})-C(O)(C_1-C_3$
 alkyl), $-NHC(O)NH(C_1-C_3 \text{ alkyl})$,
 $-NHC(O)N(C_1-C_3 \text{ alkyl})C(O)NH(C_1-C_3 \text{ alkyl})$, $-C_1-C_3$
 alkylamino, alkenylamino, alkynylamino, $di(C_1-C_3 \text{ alkyl})$ amino,
 $-C(O)O-(C_1-C_3 \text{ alkyl})$, $-C(O)NH-(C_1-C_3 \text{ alkyl})$, $-CH=NOH$,
 $-PO_3H_2$, $-OPO_3H_2$, $-C(O)N(C_1-C_3 \text{ alkyl})_2$, haloalkyl,
 alkoxyalkoxy, carboxaldehyde, carboxamide, cycloalkyl,
 cycloalkenyl, cycloalkynyl, cycloalkylalkyl, aryl, aroyl, aryloxy,
 arylamino, biaryl, thioaryl, diarylamino, heterocyclyl, alkylaryl,
 aralkenyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, sulfonyl,
 $-SO_2-(C_1-C_3 \text{ alkyl})$, $-SO_3-(C_1-C_3 \text{ alkyl})$, sulfonamido,
 aryloxyalkyl, carboxyl, carbamate and $-C(O)NH(\text{benzyl})$; and
 $R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19},$
 R^{20}, R^{21}, R^{22} and R^{23} are each independently selected from the
 group consisting of hydrogen, halogen, hydroxyl, alkyl, alkenyl,
 alkynyl, alkoxy, alkenoxy, alkynoxy, thioalkoxy, hydroxyalkyl,
 aliphatic acyl, $-CF_3$, $-NO_2$, amino, $-CN$, carboxy, $-N(C_1-C_3$
 alkyl) $-C(O)(C_1-C_3 \text{ alkyl})$, $-NHC(O)NH(C_1-C_3 \text{ alkyl})$,
 $-NHC(O)N(C_1-C_3 \text{ alkyl})C(O)NH(C_1-C_3 \text{ alkyl})$, $-C_1-C_3$
 alkylamino, alkenylamino, alkynylamino, $di(C_1-C_3 \text{ alkyl})$ amino,
 $-C(O)O-(C_1-C_3 \text{ alkyl})$, $-C(O)NH-(C_1-C_3 \text{ alkyl})$, $-CH=NOH$,
 $-PO_3H_2$, $-OPO_3H_2$, $-C(O)N(C_1-C_3 \text{ alkyl})_2$, haloalkyl,
 alkoxyalkoxy, carboxaldehyde, carboxamide, cycloalkyl,
 cycloalkenyl, cycloalkynyl, cycloalkylalkyl, aryl, aroyl, aryloxy,
 arylamino, biaryl, thioaryl, diarylamino, heterocyclyl, alkylaryl,

WO 02/13821

PCT/US01/41738

6

aralkenyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, sulfonyl,
 $-\text{SO}_2-(\text{C}_1-\text{C}_3 \text{ alkyl})$, $-\text{SO}_3-(\text{C}_1-\text{C}_3 \text{ alkyl})$, sulfonamido,
 aryloxyalkyl, carboxyl, carbamate and $-\text{C}(\text{O})\text{NH}(\text{benzyl})$;
 wherein $\text{R}^1, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{11}, \text{R}^{12}, \text{R}^{13}, \text{R}^{14}, \text{R}^{15},$
 $\text{R}^{16}, \text{R}^{17}, \text{R}^{18}, \text{R}^{19}, \text{R}^{20}, \text{R}^{21}, \text{R}^{22}$ and R^{23} are unsubstituted or
 substituted with at least one electron donating or electron
 withdrawing group;

and pharmaceutically acceptable salts thereof;


with the proviso that when T is $-\text{NR}^6\text{R}^7$, R^1 is hydrogen and n is zero, R^6
 and R^7 are not both hydrogen;

and the proviso that when T is $-\text{OH}$, n is one, and R^4 and R^5 are each
 hydrogen, R^1 is not triphenylmethyl;

and the proviso that when T is $-\text{C}(\text{O})\text{R}^{13}$ and n is zero, R^{13} is not
 hydrogen or a chiral moiety.

For presently preferred compounds of Formula II, R^1 may be hydrogen;
 R^3 may be hydrogen or lower alkyl; R^4 and R^5 may each be hydrogen, halogen,
 hydroxyl, lower alkyl, alkenyl, alkynyl or aryl; and $\text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{11}, \text{R}^{12},$
 $\text{R}^{13}, \text{R}^{14}, \text{R}^{15}, \text{R}^{16}, \text{R}^{17}, \text{R}^{18}, \text{R}^{19}, \text{R}^{20}, \text{R}^{21}, \text{R}^{22}$ and R^{23} may each be hydrogen,
 lower alkyl, alkenyl, alkynyl, aryl or heterocyclyl. Presently preferred
 compounds of Formula II have T as $-\text{N}(\text{R}^8)\text{C}(\text{NR}^9)\text{R}^{10},$
 $-\text{OC}(\text{O})\text{R}^{12}, -\text{C}(\text{O})\text{R}^{13}, -\text{C}(\text{O})\text{NH}_2, -\text{C}(\text{N}-\text{OH})\text{H}, -\text{SC}(\text{S})\text{R}^{14}, -\text{NR}^{15}\text{C}(\text{S})\text{R}^{16},$
 $-\text{NR}^{17}\text{C}(\text{O})\text{R}^{18}, -\text{SC}(\text{NR}^{19})\text{R}^{20}$ or $-\text{OC}(\text{NR}^{21})\text{R}^{22}$ when n is zero or T as $-\text{NR}^6\text{R}^7,$
 $-\text{CN}, -\text{OH}, -\text{H}, -\text{OR}^{11}$ or R^{23} when n is one.

More specifically, the compounds of this invention may be described by
 Formula III below



Formula III

wherein T is selected from the group consisting of $-\text{N}(\text{R}^8)\text{C}(\text{NR}^9)\text{R}^{10},$
 $-\text{OC}(\text{O})\text{R}^{12}, -\text{C}(\text{O})\text{R}^{13}, -\text{C}(\text{O})\text{NH}_2, -\text{C}(\text{N}-\text{OH})\text{H}, -\text{SC}(\text{S})\text{R}^{14},$

WO 02/13821

PCT/US01/41738

7

$-\text{NR}^{15}\text{C}(\text{S})\text{R}^{16}$, $-\text{NR}^{17}\text{C}(\text{O})\text{R}^{18}$, $-\text{SC}(\text{NR}^{19})\text{R}^{20}$ and $-\text{OC}(\text{NR}^{21})\text{R}^{22}$;

R^3 is selected from the group consisting of hydrogen and lower alkyl;

and,

R^8 , R^9 , R^{10} , R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} , R^{19} , R^{20} , R^{21} and R^{22} are each

5 independently selected from the group consisting of hydrogen, lower alkyl, alkenyl, alkynyl, aryl and heterocyclyl;

wherein R^3 , R^8 , R^9 , R^{10} , R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} , R^{19} , R^{20} ,

R^{21} and R^{22} are unsubstituted or substituted with at least

one electron donating or electron withdrawing group;


10 and pharmaceutically acceptable salts thereof;

with the proviso that when T is $-\text{C}(\text{O})\text{R}^{13}$, R^{13} is not

hydrogen or a chiral moiety.

More specifically, the compounds of this invention may be described by

Formula IV below



15 Formula IV

wherein T is selected from the group consisting of $-\text{NR}^6\text{R}^7$,

$-\text{CN}$, $-\text{OH}$, $-\text{H}$, $-\text{OR}^{11}$ and R^{23} ;

R^3 is selected from the group consisting of hydrogen and methyl;

R^4 and R^5 are each independently selected from the group consisting of

20 hydrogen, halogen, hydroxyl, lower alkyl, alkenyl, alkynyl and aryl; and,

R^6 , R^7 , R^{11} and R^{23} are each independently selected from the group consisting of hydrogen, lower alkyl, alkenyl, alkynyl, aryl and heterocyclyl;

25 wherein R^3 , R^4 , R^5 , R^6 , R^7 , R^{11} and R^{23} are unsubstituted or substituted with at least one electron donating or electron withdrawing group;

WO 02/13821

PCT/US01/41738

8

and pharmaceutically acceptable salts thereof.

Formulae I-IV also encompass esters, carbamates, amins, amides, optical isomers or pro-drugs thereof.

Presently preferred compounds include 4-(*trans*-2-cyano-cyclopropyl) imidazole, 4-(*trans*-2-aminocarbonyl-cyclopropyl) imidazole, 4-(*trans*-2-amidino-cyclopropyl) imidazole, 4-(*trans*-2-aminomethyl-cyclopropyl) imidazole, 4-(*trans*-2-*N*-hydroxyimino-cyclopropyl) imidazole, 4-(*trans*-2-hydroxymethyl-cyclopropyl) imidazole, 4-(*trans*-2-*N*-methylamidino-cyclopropyl) imidazole, 4-(*trans*-2-aminomethyl-2-methyl-cyclopropyl) imidazole, 4-(*trans*-2-amidino-2-methyl-cyclopropyl) imidazole and pharmaceutically acceptable salts thereof. The present invention also relates to pharmaceutical compositions comprising a physiologically acceptable diluent and at least one compound of the present invention; and a method for regulation of histamine H₃ receptors in a mammal by agonism, antagonism, or inverse agonism of said receptors, comprising administering to a mammal in need of such regulation a therapeutic amount of a compound of the present invention.

Detailed Description of the Invention

Definitions of Terms

The term "alkyl" as used herein, alone or in combination, refers to C₁-C₁₂ straight or branched, substituted or unsubstituted saturated chain radicals derived from saturated hydrocarbons by the removal of one hydrogen atom, unless the term alkyl is preceded by a C_x-C_y designation. Representative examples of alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, and tert-butyl among others.

The term "alkenyl" as used herein, alone or in combination, refers to a substituted or unsubstituted straight-chain or substituted or unsubstituted branched-chain alkenyl radical containing from 2 to 10 carbon atoms. Examples of such radicals include, but are not limited to, ethenyl, E- and Z-pentenyl, decenyl and the like.

The term "alkynyl" as used herein, alone or in combination, refers to a substituted or unsubstituted straight or substituted or unsubstituted branched

WO 02/13821

PCT/US01/41738

9

chain alkynyl radical containing from 2 to 10 carbon atoms. Examples of such radicals include, but are not limited to ethynyl, propynyl, propargyl, butynyl, hexynyl, decynyl and the like.

5 The term "lower" modifying "alkyl", "alkenyl", "alkynyl" or "alkoxy" refers to a C₁-C₆ unit for a particular functionality. For example lower alkyl means C₁-C₆ alkyl.

The term "aliphatic acyl" as used herein, alone or in combination, refers to radicals of formula alkyl-C(O)-, alkenyl-C(O)- and alkynyl-C(O)- derived from an alkane-, alkene- or alkynecarboxylic acid, wherein the terms "alkyl",
10 "alkenyl" and "alkynyl" are as defined above. Examples of such aliphatic acyl radicals include, but are not limited to, acetyl, propionyl, butyryl, valeryl, 4-methylvaleryl, acryloyl, crotyl, propiolyl and methylpropiolyl, among others.

The term "cycloalkyl" as used herein refers to an aliphatic ring system having 3 to 10 carbon atoms and 1 to 3 rings, including, but not limited to
15 cyclopropyl, cyclopentyl, cyclohexyl, norbornyl, and adamantyl among others. Cycloalkyl groups can be unsubstituted or substituted with one, two or three substituents independently selected from lower alkyl, haloalkyl, alkoxy, thioalkoxy, amino, alkylamino, dialkylamino, hydroxy, halo, mercapto, nitro, carboxaldehyde, carboxy, alkoxycarbonyl and carboxamide. "Cycloalkyl"
20 includes cis or trans forms. Furthermore, the substituents may either be in endo or exo positions in the bridged bicyclic systems.

The term "cycloalkenyl" as used herein alone or in combination refers to a cyclic carbocycle containing from 4 to 8 carbon atoms and one or more
25 double bonds. Examples of such cycloalkenyl radicals include, but are not limited to, cyclopentenyl, cyclohexenyl, cyclopentadienyl and the like. The term "cycloalkylalkyl" as used herein refers to a cycloalkyl group appended to a lower alkyl radical, including, but not limited to cyclohexylmethyl.

The term "halo" or "halogen" as used herein refers to I, Br, Cl or F.

The term "haloalkyl" as used herein refers to a lower alkyl radical, to
30 which is appended at least one halogen substituent, for example chloromethyl, fluoroethyl, trifluoromethyl and pentafluoroethyl among others.

The term "alkoxy" as used herein, alone or in combination, refers to an

WO 02/13821

PCT/US01/41738

10

alkyl ether radical, wherein the term "alkyl" is as defined above. Examples of suitable alkyl ether radicals include, but are not limited to, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy and the like.

5 The term "alkenoxy" as used herein, alone or in combination, refers to a radical of formula alkenyl-O-, provided that the radical is not an enol ether, wherein the term "alkenyl" is as defined above. Examples of suitable alkenoxy radicals include, but are not limited to, allyloxy, E- and Z- 3-methyl-2-propenoxy and the like.

10 The term "alkynoxy" as used herein, alone or in combination, refers to a radical of formula alkynyl-O-, provided that the radical is not an -ynol ether. Examples of suitable alkynoxy radicals include, but are not limited to, propargyloxy, 2-butynyloxy and the like.

15 The term "carboxyl" as used herein refers to a carboxylic acid radical, -C(O)OH.

 The term "carboxy" as used herein refers to -C(O)-.

 The term "thioalkoxy" refers to a thioether radical of formula alkyl-S-, wherein "alkyl" is as defined above.

20 The term "carboxaldehyde" as used herein refers to -C(O)R wherein R is hydrogen.

 The terms "carboxamide" or "amide" as used herein refer to -C(O)NR_aR_b wherein R_a and R_b are each independently hydrogen, alkyl or any other suitable substituent.

25 The term "alkoxyalkoxy" as used herein refers to R_cO-R_dO- wherein R_c is lower alkyl as defined above and R_d is alkylene wherein alkylene is -(CH₂)_n- wherein n' is an integer from 1 to 6. Representative examples of alkoxyalkoxy groups include methoxymethoxy, ethoxymethoxy, t-butoxymethoxy among others.

30 The term "alkylamino" as used herein refers to R_eNH- wherein R_e is a lower alkyl group, for example, ethylamino, butylamino, among others.

 The term "alkenylamino", as used herein, alone or in combination, refers to a radical of formula alkenyl-NH-or (alkenyl)₂N-, wherein the term "alkenyl"

WO 02/13821

PCT/US01/41738

11

is as defined above, provided that the radical is not an enamine. An example of such alkenylamino radical is the allylamino radical.

The term "alkynylamino" as used herein, alone or in combination, refers to a radical of formula alkynyl-NH- or (alkynyl)₂N- wherein the term "alkynyl" is as defined above, provided that the radical is not an amine. An example of such alkynylamino radicals is the propargyl amino radical.

The term "dialkylamino" as used herein refers to R_fR_gN- wherein R_f and R_g are independently selected from lower alkyl, for example diethylamino, and methyl propylamino, among others.

The term "amino" as used herein refers to H₂N-.

The term "alkoxycarbonyl" as used herein refers to an alkoxyl group as previously defined appended to the parent molecular moiety through a carbonyl group. Examples of alkoxycarbonyl include methoxycarbonyl, ethoxycarbonyl, and isopropoxycarbonyl among others.

The term "aryl" or "aromatic" as used herein alone or in combination refers to a substituted or unsubstituted carbocyclic aromatic group having about 6 to 12 carbon atoms such as phenyl, naphthyl, indenyl, indanyl, azulenyl, fluorenyl and anthracenyl; or a heterocyclic aromatic group which is an aromatic ring containing at least one endocyclic N, O or S atom such as furyl, thienyl, pyridyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, 2-pyrazolynyl, pyrazolidinyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,3-triazolyl, 1,3,4-thiadiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazinyl, 1,3,5-trithianyl, indolizynyl, indolyl, isoindolyl, 3H-indolyl, indolynyl, benzo[b]furanyl, 2,3-dihydrobenzofuranyl, benzo[b]thiophenyl, 1H-indazolyl, benzimidazolyl, benzthiazolyl, purinyl, 4H-quinolizynyl, isoquinolynyl, cinnolynyl, phthalazinyl, quinazolynyl, quinoxalynyl, 1,8-naphthridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxyazinyl, pyrazolo[1,5-c]triazinyl and the like. "Arylalkyl" and "alkylaryl" employ the term "alkyl" as defined above. Rings may be multiply substituted.

The term "aralkyl" as used herein, alone or in combination, refers to an aryl substituted alkyl radical, wherein the terms "alkyl" and "aryl" are as defined above. Examples of suitable aralkyl radicals include, but are not

WO 02/13821

PCT/US01/41738

12

limited to, phenylmethyl, phenethyl, phenylhexyl, diphenylmethyl, triphenylmethyl, pyridylmethyl, tetrazolyl methyl, furylmethyl, imidazolyl methyl, indolylmethyl, thienylpropyl and the like.

5 The term "aralkenyl" as used herein, alone or in combination, refers to an aryl substituted alkenyl radical, wherein the terms "aryl" and "alkenyl" are as defined above.

The term "arylamino" as used herein, alone or in combination, refers to a radical of formula aryl-NH-, wherein "aryl" is as defined above. Examples of arylamino radicals include, but are not limited to, phenylamino(anilido), naphthylamino, 2-, 3-, and 4- pyridylamino and the like.

The term "biaryl" as used herein, alone or in combination, refers to a radical of formula aryl-aryl, wherein the term "aryl" is as defined above.

10 The term "thioaryl" as used herein, alone or in combination, refers to a radical of formula aryl-S-, wherein the term "aryl" is as defined above. An example of a thioaryl radical is the thiophenyl radical.

The term "aroyl" as used herein, alone or in combination, refers to a radical of formula aryl-CO-, wherein the term "aryl" is as defined above. Examples of suitable aromatic acyl radicals include, but are not limited to, benzoyl, 4-halobenzoyl, 4-carboxybenzoyl, naphthoyl, pyridylcarbonyl and the like.

20 The term "heterocyclyl" as used herein, alone or in combination, refers to a non-aromatic 3- to 10- membered ring containing at least one endocyclic N, O, or S atom. The heterocycle may be optionally aryl-fused. The heterocycle may also optionally be substituted with at least one substituent which is independently selected from the group consisting of hydrogen, halogen, hydroxyl, amino, nitro, trifluoromethyl, trifluoromethoxy, alkyl, aralkyl, alkenyl, alkynyl, aryl, cyano, carboxy, carboalkoxy, carboxyalkyl, oxo, arylsulfonyl and aralkylaminocarbonyl among others.

25 The term "alkylheterocyclyl" as used herein refers to an alkyl group as previously defined appended to the parent molecular moiety through a heterocyclyl group.

The term "heterocyclylalkyl" as used herein refers to a heterocyclyl

WO 02/13821

PCT/US01/41738

13

group as previously defined appended to the parent molecular moiety through an alkyl group.

The term "aminal" as used herein refers to a hemi-acetal of the structure $R_hC(NR_iR_j)(NR_kR_l)-$ wherein R_h , R_i , R_j , R_k and R_l are each independently
5 hydrogen, alkyl or any other suitable substituent.

The term "ester" as used herein refers to $-C(O)R_m$, wherein R_m is hydrogen, alkyl or any other suitable substituent.

The term "carbamate" as used herein refers to compounds based on carbamic acid, $NH_2C(O)OH$.

10 Use of the above terms is meant to encompass substituted and unsubstituted moieties. Substitution may be by one or more groups such as alcohols, ethers, esters, amides, sulfones, sulfides, hydroxyl, nitro, cyano, carboxy, amines, heteroatoms, lower alkyl, lower alkoxy, lower
alkoxycarbonyl, alkoxyalkoxy, acyloxy, halogens, trifluoromethoxy,
15 trifluoromethyl, alkyl, aralkyl, alkenyl, alkynyl, aryl, cyano, carboxy, carboalkoxy, carboxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, alkylheterocyclyl, heterocyclylalkyl, oxo, arylsulfonyl and
aralkylaminocarbonyl or any of the substituents of the preceding paragraphs or any of those substituents either attached directly or by suitable linkers. The
20 linkers are typically short chains of 1-3 atoms containing any combination of -C-, $-C(O)-$, $-NH-$, $-S-$, $-S(O)-$, $-O-$, $-C(O)O-$ or $-S(O)O-$. Rings may be substituted multiple times.

The terms "electron-withdrawing" or "electron-donating" refer to the ability of a substituent to withdraw or donate electrons relative to that of
25 hydrogen if hydrogen occupied the same position in the molecule. These terms are well-understood by one skilled in the art and are discussed in Advanced Organic Chemistry by J. March, 1985, pp. 16-18, incorporated herein by reference. Electron withdrawing groups include halo, nitro, carboxyl, lower
alkenyl, lower alkynyl, carboxaldehyde, carboxyamido, aryl, quaternary
30 ammonium, trifluoromethyl, and aryl lower alkanoyl among others. Electron donating groups include such groups as hydroxy, lower alkyl, amino, lower alkylamino, di(lower alkyl)amino, aryloxy, mercapto, lower alkylthio, lower

WO 02/13821

PCT/US01/41738

14

alkylmercapto, and disulfide among others. One skilled in the art will appreciate that the aforesaid substituents may have electron donating or electron withdrawing properties under different chemical conditions. Moreover, the present invention contemplates any combination of substituents selected from the above-identified groups.

The most preferred electron donating or electron withdrawing substituents are halo, nitro, alkanoyl, carboxaldehyde, arylalkanoyl, aryloxy, carboxyl, carboxamide, cyano, sulfonyl, sulfoxide, heterocyclyl, guanidine, quaternary ammonium, lower alkenyl, lower alkynyl, sulfonium salts, hydroxy, lower alkoxy, lower alkyl, amino, lower alkylamino, di(lower alkyl)amino, amine lower alkyl mercapto, mercaptoalkyl, alkylthio and alkylthio.

As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from a combination of the specified ingredients in the specified amounts.

"Chiral moieties" as used herein refers to substituents having a chiral center.

"Sulfonamido" as used herein refers to $-\text{SO}_2\text{NH}_2$.

Abbreviations

Abbreviations which have been used in the schemes and the examples which follow are: LAH for lithium aluminum hydride, TFA for trifluoroacetic acid and EDTA for ethylene diamine tetraacetic acid.

A detailed description of the preparation of representative compounds of the present invention is set forth in the Examples.

The compounds of the present invention can be used in the form of pharmaceutically acceptable salts derived from inorganic or organic acids. The phrase "pharmaceutically acceptable salt" means those salts which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well-known in the art. For example, S. M. Berge et al. describe pharmaceutically acceptable salts in detail in J.

WO 02/13821

PCT/US01/41738

15

Pharmaceutical Sciences, 1977, 66: 1 *et seq.* The salts can be prepared *in situ* during the final isolation and purification of the compounds of the invention or separately by reacting a free base function with a suitable organic acid. Representative acid addition salts include, but are not limited to acetate, adipate, 5 alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphor sulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isothionate), lactate, maleate, methane sulfonate, nicotinate, 2-naphthalene sulfonate, oxalate, palmitoate, pectinate, persulfate, 3-10 phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, phosphate, glutamate, bicarbonate, p-toluenesulfonate and undecanoate. Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl and diamyl sulfates; 15 long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; arylalkyl halides like benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained. Examples of acids which can be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, 20 hydrobromic acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid.

Basic addition salts can be prepared *in situ* during the final isolation and purification of compounds of this invention by reacting a carboxylic acid-containing moiety with a suitable base such as the hydroxide, carbonate or 25 bicarbonate of a pharmaceutically acceptable metal cation or with ammonia or an organic primary, secondary or tertiary amine. Pharmaceutically acceptable salts include, but are not limited to, cations based on alkali metals or alkaline earth metals such as lithium, sodium, potassium, calcium, magnesium and aluminum salts and the like and nontoxic quaternary ammonia and amine 30 cations including ammonium, tetramethylammonium, tetraethylammonium, methylammonium, dimethylammonium, trimethylammonium, triethylammonium, diethylammonium, and ethylammonium among others.

WO 02/13821

PCT/US01/41738

16

Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, piperazine and the like.

5 Dosage forms for topical administration of a compound of this invention include powders, sprays, ointments and inhalants. The active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives, buffers or propellants which can be required. Ophthalmic formulations, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.

10 Actual dosage levels of active ingredients in the pharmaceutical compositions of this invention can be varied so as to obtain an amount of the active compound(s) which is effective to achieve the desired therapeutic response for a particular patient. The selected dosage level will depend upon the activity of the particular compound, the route of administration, the severity
15 of the condition being treated and the condition and prior medical history of the patient being treated. However, it is within the skill of the art to start doses of the compound at levels lower than required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.

When used in the above or other treatments, a therapeutically effective
20 amount of one of the compounds of the present invention can be employed in pure form or, where such forms exist, in pharmaceutically acceptable salt, ester or prodrug form. Alternatively, the compound can be administered as a pharmaceutical composition containing the compound of interest in combination with one or more pharmaceutically acceptable excipients. The
25 phrase "therapeutically effective amount" of the compound of the invention means a sufficient amount of the compound to treat disorders, at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of
30 sound medical judgement. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific

WO 02/13821

PCT/US01/41738

17

compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of the compound at levels lower than required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.

The total daily dose of the compounds of this invention administered to a human or lower animal may range from about 0.0001 to about 1000 mg/kg/day. For purposes of oral administration, more preferable doses can be in the range of from about 0.001 to about 5 mg/kg/day. If desired, the effective daily dose can be divided into multiple doses for purposes of administration; consequently, single dose compositions may contain such amounts or submultiples thereof to make up the daily dose.

The present invention also provides pharmaceutical compositions that comprise compounds of the present invention formulated together with one or more non-toxic pharmaceutically acceptable carriers. The pharmaceutical compositions can be specially formulated for oral administration in solid or liquid form, for parenteral injection or for rectal administration.

The pharmaceutical compositions of this invention can be administered to humans and other mammals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments or drops), buccally or as an oral or nasal spray. The term "parenterally," as used herein, refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

In another aspect, the present invention provides a pharmaceutical composition comprising a component of the present invention and a physiologically tolerable diluent. The present invention includes one or more compounds as described above formulated into compositions together with one or more non-toxic physiologically tolerable or acceptable diluents, carriers,

WO 02/13821

PCT/US01/41738

18

adjuvants or vehicles that are collectively referred to herein as diluents, for parenteral injection, for intranasal delivery, for oral administration in solid or liquid form, for rectal or topical administration, or the like.

5 The compositions can also be delivered through a catheter for local delivery at a target site, via an intracoronary stent (a tubular device composed of a fine wire mesh), or via a biodegradable polymer. The compounds may also be complexed to ligands, such as antibodies, for targeted delivery.

10 Compositions suitable for parenteral injection may comprise physiologically acceptable, sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propyleneglycol, polyethyleneglycol, glycerol, and the like), vegetable oils (such as olive oil), injectable organic esters such as ethyl oleate, and
15 suitable mixtures thereof.

These compositions can also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may
20 also be desirable to include isotonic agents, for example sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.

25 Suspensions, in addition to the active compounds, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.

30 Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.

In some cases, in order to prolong the effect of the drug, it is desirable to

WO 02/13821

PCT/US01/41738

19

slow the absorption of the drug from subcutaneous or intramuscular injection. This can be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.

Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.

The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.

Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound may be mixed with at least one inert, pharmaceutically acceptable excipient or carrier, such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol and silicic acid; b) binders such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia; c) humectants such as glycerol; d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates and sodium carbonate; e) solution retarding agents such as paraffin; f) absorption accelerators such as quaternary ammonium compounds; g) wetting agents such as cetyl alcohol and glycerol monostearate; h) absorbents such as kaolin and bentonite clay and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate and mixtures thereof. In the case of capsules, tablets and

WO 02/13821

PCT/US01/41738

20

pills, the dosage form may also comprise buffering agents.

Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

5 The solid dosage forms of tablets, dragees, capsules, pills and granules can be prepared with coatings and shells such as enteric coatings and other coatings well-known in the pharmaceutical formulating art. They may optionally contain opacifying agents and may also be of a composition such that they release the active ingredient(s) only, or preferentially, in a certain part of
10 the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.

The active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients.

15 Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene
20 glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan and mixtures thereof.

25 Besides inert diluents, the oral compositions may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring and perfuming agents.

30 Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.

WO 02/13821

PCT/US01/41738

21

Compounds of the present invention can also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals which are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to a compound of the present invention, stabilizers, preservatives, excipients and the like. The preferred lipids are natural and synthetic phospholipids and phosphatidyl cholines (lecithins) used separately or together.

Methods to form liposomes are known in the art. See, for example, Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N.Y. (1976), p. 33 *et seq.*

The term "pharmaceutically acceptable prodrugs" as used herein represents those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention. Prodrugs of the present invention may be rapidly transformed *in vivo* to the parent compound of the above formula, for example, by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, V. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press (1987), hereby incorporated by reference.

The present invention contemplates both synthetic compounds of Formulae I-IV of the present invention, as well as compounds formed by *in vivo* conversion to compounds of the present invention.

Compounds of the present invention may exist as stereoisomers wherein asymmetric or chiral centers are present. These stereoisomers are "R" or "S" depending on the configuration of substituents around the chiral carbon atom.

WO 02/13821

PCT/US01/41738

22

The present invention contemplates various stereoisomers and mixtures thereof. Stereoisomers include enantiomers and diastereomers, and mixtures of enantiomers or diastereomers. Individual stereoisomers of compounds of the present invention may be prepared synthetically from commercially available starting materials which contain asymmetric or chiral centers or by preparation of racemic mixtures followed by resolution well-known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary or (2) direct separation of the mixture of optical enantiomers on chiral chromatographic columns.


The compounds of the invention can exist in unsolvated as well as solvated forms, including hydrated forms, such as hemi-hydrates. In general, the solvated forms, with pharmaceutically acceptable solvents such as water and ethanol among others are equivalent to the unsolvated forms for the purposes of the invention.

Compounds of Formula I may be prepared according to the syntheses depicted in Scheme I below.

WO 02/13821

PCT/US01/41738

23



WO 02/13821

PCT/US01/41738

24

The aldehyde 1 was prepared according to a procedure described in Phillips et al., US 6,008,240. Using aldehyde 1 as the starting material, a number of compounds of Formula I may be prepared. For example, the oxime cyclopropyl imidazole 2 was synthesized from aldehyde 1 by removing the trityl protective group using HCl followed by treatment with hydroxyamine, and alcohol 3 was obtained by reducing aldehyde 1.

When treated with hydroxyamine without removing the protective group followed by dehydration, the aldehyde 1 gave rise to the nitrile 4, which upon reduction furnished the aminomethyl product 5. The nitrile 4 was also converted to the amidine 7, using alkylaluminum in the presence of an amine. In addition, hydrolysis of the nitrile 4 under acidic conditions afforded amide 6.

The following Examples are presented to describe preferred embodiments and utilities of the invention and are not meant to limit the invention unless otherwise stated in the claims appended hereto.

Example 1

Preparation of *N*-triphenylmethyl-4- (*trans*-2-cyano-cyclopropyl) imidazole

To a solution of hydroxylamine hydrochloride (816 mg, 12 mmol) in anhydrous acetonitrile (35 mL), were added triethylamine (1.6 ml, 12 mmol), and 2-[1-(triphenylmethyl) imidazol-4-yl]cyclopropanecarbaldehyde (4.0 g, 11 mmol) The resulting mixture was stirred for about 2 hours followed by the addition of phthalic anhydride (1.6 g, 11 mmol) under nitrogen. Then the reaction mixture was heated under reflux for 8 hours, concentrated under reduced pressure, diluted with 5% aqueous ammonia (30 mL), and extracted with ethyl acetate (3 X 40 ml). The organic layer was dried with MgSO₄, and then evaporated under reduced pressure. The resulting residue was purified on a silica gel column using ethyl acetate/hexane (v/v: 1/6) as the eluting solvent to give the title compound as a pale yellow solid (2.4 g, 64 % yield).

Preparation of 4-(*trans*-2-cyano-cyclopropyl) imidazole trifluoroacetic

WO 02/13821

PCT/US01/41738

25

acid salt

A mixture of *N*-triphenylmethyl-4-(*trans*-2-cyano-cyclopropyl) imidazole (200 mg, 0.54 mmol) and trifluoroacetic acid (TFA) (10 mL) was stirred at room temperature for 1-3 hours. The TFA was evaporated under reduced pressure. The resulting mixture was diluted with distilled water (5 mL) and extracted with ether (3 X 15 mL). The aqueous layer was lyophilized to give the product as a solid (73 mg, 55% yield).

Example 2

Preparation of 4-(*trans*-2-aminocarbonyl-cyclopropyl) imidazole trifluoroacetic acid salt

A mixture of *N*-triphenylmethyl-4- (*trans*-2-cyano-cyclopropyl) imidazole (150 mg, 0.4 mmol) and concentrated hydrogen chloride (37%, 5 mL) was heated to 40°C for 1.5 hours and then diluted with water (20 mL). The aqueous solution was extracted with ether (3 X 15 mL) and lyophilized to give the amide product (53 mg, 50 % yield).

Example 3

Preparation of *N*-triphenylmethyl-4-(*trans*-2-amidino-cyclopropyl) imidazole

A solution of trimethylaluminium in toluene (2M, 0.6 mL, 1.2 mmol) was slowly added to a suspension of ammonium chloride (64 mg, 12 mmol) in dry toluene (5 mL) at 0°C under nitrogen. The resulting mixture was warmed to 25°C and stirred for 3 hours until gas evolution had ceased. Then, *N*-triphenylmethyl-4- (*trans*-2-cyano-cyclopropyl) imidazole (200 mg, 0.53 mmol) in dry toluene (10 mL) was added and the reaction mixture was heated to 80°C for 18 hours under nitrogen, slowly poured into a slurry of silica gel (15 g) in chloroform (50 mL), and stirred for 10 minutes. The silica was filtered and washed with methanol. The combined solvent mixture was concentrated under vacuum and the residue was purified on a silica gel column using 85/15/5 (v/v/v) methylene chloride /methanol/ ammonium hydroxide as the eluent to give a white solid (140 mg, 68 % yield).

WO 02/13821

PCT/US01/41738

26

Preparation of 4-(*trans*-2-amidino-cyclopropyl) imidazole di-trifluoroacetic acid salt

A mixture of *N*-triphenylmethyl-4- (*trans*-2-amidino-cyclopropyl) imidazole (100 mg, 0.26 mmol) and trifluoroacetic acid (TFA) (10 mL) was stirred at room temperature for 1-3 hours. The TFA was evaporated under reduced pressure, and the residue was diluted with distilled water (5 mL) and extracted with ether (3 X 10 mL). The aqueous layer was lyophilized to give the product as a solid (41 mg, 43% yield).

10 Example 4

Preparation of *N*-triphenylmethyl-4- (*trans*-2-aminomethyl-cyclopropyl) imidazole

To a solution of 2-[1-(triphenylmethyl) imidazol-4-yl] cyclopropanecarbonitrile (200 mg, 0.53 mmol) in dry diethyl ether (20 mL) was added lithium aluminum hydride (40 mg, 1.05 mmol) portion-wise at 0°C under nitrogen. The reaction was stirred for 9 hours at room temperature. Water (0.5 mL) was added followed by the addition of a 15% sodium hydroxide solution (2.0 mL). The mixture was extracted with ethyl acetate. The organic layer was dried with MgSO₄ and concentrated. The resulting residue was eluted through a silica gel column using CH₂Cl₂ / MeOH / NH₄OH (85: 15: 5) to give a white solid amine product (130 mg, 65 % yield).

Preparation of 4-(*trans*-2-aminomethyl-cyclopropyl) imidazole di-hydrochloric acid salt

To a solution of *N*-triphenylmethyl-4-(*trans*-2-aminomethyl-cyclopropyl) imidazole (100 mg, 0.26 mmol) in methanol (15 mL) was added 2N HCl solution (2.5 mL). The mixture was stirred at 60°C for 2 hours and then concentrated. The resulting residue was extracted with ether (3 X 20 ml). The aqueous layer was lyophilized to give the product (47 mg, 83% yield).

30 Example 5

Preparation of 4-(*trans*-2-hydrocarbonyl-cyclopropyl) imidazole
To a solution of *N*-triphenylmethyl-4- (*trans*-2-hydrocarbonyl-cyclopropyl)

WO 02/13821

PCT/US01/41738

27

imidazole (1.0 g, 2.65 mmol) in methanol (20 mL) was added 2N HCl (3 mL). The mixture was stirred at 60 °C for about 2 hours and concentrated under reduced pressure. The reaction mixture was then diluted with water (50 mL), and its pH was adjusted to 8.0 with saturated potassium carbonate solution. The
5 resulting mixture was saturated with sodium chloride and then extracted with ethyl acetate (3 X 50 mL). The organic layer was dried with sodium sulfate and the solvent was evaporated to give a yellow oil (0.3 g, 82 % yield).

Preparation of 4-(*trans*-2-*N*-hydroxyimino-cyclopropyl) imidazole

To a solution of hydroxylamine hydrochloride (115 mg, 1.6 mmol) and
10 4-(*trans*-2-hydrocarbonyl-cyclopropyl) imidazole (150 mg, 1.6 mmol) in acetonitrile was added triethylamine (0.24 mL, 1.6 mmol). The mixture was stirred at room temperature for about 2 hours to give a precipitate, which was filtered. The filtrate was concentrated under vacuum and the residue was purified on a silica gel column, using a mixed solvent of CH₂Cl₂ / MeOH /
15 NH₄OH (85:15:5) to give the title product (103 mg, 43 % yield).

Example 6

Preparation of *N*-triphenylmethyl-4- (*trans*-2-hydroxymethyl-cyclopropyl) imidazole trifluoroacetic acid salt

To a solution of *N*-triphenylmethyl-4- (*trans*-2-hydrocarbonyl-cyclopropyl) imidazole (200 mg, 0.53 mmol) in dry diethyl ether (20 mL) was added lithium aluminum hydride (40 mg, 1.05 mmol) at 0 °C under nitrogen. The reaction was stirred for 12 hours at room temperature, and water (0.5 mL) was added followed by the addition of 15% sodium hydroxide solution (2.0
25 mL). The reaction mixture was extracted with ethyl acetate. The organic layer was dried with MgSO₄ and concentrated under vacuum to give the product as a white solid (130 mg, 65 % yield).

Preparation of 4-(*trans*-2-hydroxymethyl-cyclopropyl) imidazole
30 trifluoroacetic acid salt

A mixture of *N*-triphenylmethyl-4- (*trans*-2-hydroxymethyl-cyclopropyl) imidazole (100 mg, 0.26 mmol) and trifluoroacetic acid (TFA) (10

WO 02/13821

PCT/US01/41738

28

mL) was stirred at room temperature for 1-3 hours. The TFA was evaporated under reduced pressure. The resulting mixture was diluted with distilled water (5 mL) and extracted with ether (3 X 15 mL). The aqueous layer was lyophilized to give the product (61 mg, 93 % yield).

5

Example 7

Preparation of *N*-triphenylmethyl-4- (*trans*-2-*N*-methyamidino-cyclopropyl) imidazole

A solution of trimethylaluminium in toluene (2M, 0.54 mL, 1.08 mmol) was slowly added to a suspension of methylamine hydrochloride (73 mg, 1.08 mmol) in dry toluene (15 mL) at 0 °C under nitrogen. The resulting mixture was warmed to 25 °C and stirred for 3 hours until gas evolution had ceased. Then, *N*-triphenylmethyl-4- (*trans*-2-cyano- cyclopropyl) imidazole (200 mg, 0.53 mmol) in dry toluene (10 mL) was added, and the solution was heated to 80°C for 18 hours under nitrogen. The reaction mixture was slowly poured into a slurry of 15 g of silica gel in chloroform (50 mL), stirred for 10 minutes, and filtered. The silica gel was further washed with methanol. The combined solvent was concentrated under vacuum to give a residue, which was purified on a silica gel column, using a mixed solvent consisting of methylene chloride /methanol/ ammonium hydroxide 85/15/5 (v/v/v) as the eluent to give the *N*-methyl amidine product (89 mg, 45% yield).

15

20

Preparation of 4-(*trans*-2-*N*-methyamidino-cyclopropyl) imidazole dihydrochloric acid salt

To a solution of *N*-triphenylmethyl-4-(*trans*-2-*N*-methyamidino-cyclopropyl) imidazole (55 mg, 0.15 mmol) in methanol (15 mL) was added 2N HCl solution (2.5 mL). The mixture was stirred at 60°C for 2 hours and then concentrated. The resulting residue was extracted with ether (3 X 15 mL), and the aqueous layer was lyophilized to give the final product (25 mg, 74% yield).

25

30

Example 8

Histamine H₃ receptor affinity was determined in rat cerebral cortical membranes with [³H]NAMHA as previously described (Tedford *et al.*, 1995).

WO 02/13821

PCT/US01/41738

29

Animals were euthanized by rapid decapitation and cerebral cortical tissues were harvested and frozen on dry ice. Cerebral cortical membranes were prepared in 50 mM sodium-phosphate buffered saline (pH 7.5 at 4°C) containing: EDTA (10 mM), phenylmethylsulfonyl fluoride (0.1 mM),
5 chymostatin and leupeptin (each 0.2 mg/50 mL). The final membrane pellets were resuspended in water and stored frozen at -80°C prior to use. Protein concentrations were determined using the Coomassie Plus Protein Assay (Pierce, Rockford IL).

Competition binding was carried out in a total volume of 0.2 mL of 50
10 mM sodium-phosphate buffer (pH 7.4) using ~1 nM [³H]NAMHA ([³H]-N^α-methylhistamine, available from NEN Research Products of Boston, MA) and 0.003 to 10,000 nM concentrations of the test compounds. Non-specific binding was determined using 10 μM thioperamide. Samples were incubated for 40 minutes at 25°C and subsequently filtered through Whatman GF/C glass
15 fiber filters pre-soaked in binding buffer with 0.3% polyethyleneimine, using an Inotech cell harvester (Inotech Biosystems International, Lansing MI). The filters were rapidly washed three times with Tris-NaCl buffer (25 and 145 mM, respectively, pH 7.4, 4°C). Samples were quantitated using Ecolume scintillation cocktail (ICN Biomedicals; Costa Mesa CA) and a Packard model
20 1900TR liquid scintillation analyzer (Packard Instrument Co., Downers Grove IL). IC₅₀ values were extrapolated from a plot of receptor occupancy (i.e. % bound) vs. log [competitor]. Inhibition constants (*K_i*'s) were determined using the equation: $K_i = IC_{50} / (1 + ([\text{ligand}] / [K_d]))$, where *K_d* = 0.4 nM for [³H]NAMHA. In Table 1, a lower *K_i* value for binding of the competitive
25 ligand indicates that the tested compound has greater affinity for histamine H₃ receptors.

30

35

Table I

WO 02/13821

PCT/US01/41738

30

5

10

15

20

25

Example #	Name	NMR Data	Ki (nM)
Example 1	4-(<i>trans</i> -2-cyano-cyclopropyl)imidazole trifluoroacetic acid salt	δ 8.81(s, 1H), 7.42(1, 1H), 2.75 (m, 1H), 2.0 (m, 1H), 1.74 (m, 1H), 1.59 (m, 1H)	20
Example 2	4-(<i>trans</i> -2-aminocarbonyl-cyclopropyl)imidazole trifluoroacetic acid salt	δ 8.80 (s, 1H), 7.25 (s, 1H), 2.55 (m, 1H), 2.0 (m, 1H), 1.55 (m, 1H), 1.35 (m, 1H)	127
Example 3	4-(<i>trans</i> -2-amidino-cyclopropyl)imidazole di-trifluoroacetic acid salt	δ 8.84 (s, 1H), 7.45 (m, 1H), 2.8 (m, 1H), 2.23 (m, 1H), 1.9 (m, 2H).	6.7
Example 4	4-(<i>trans</i> -2-aminomethyl-cyclopropyl)imidazole di-hydrochloric acid salt	δ 8.79 (s, 1H), 7.35 (s, 1H), 3.12 (m, 1H), 2.97 (m, 1H), 2.10 (m, 1H), 1.54 (m, 1H), 1.20 (m, 2H)	4.5
Example 5	4-(<i>trans</i> -2- <i>N</i> -hydroxyimino-cyclopropyl)imidazole	δ 7.68 (m, 1H), 7.05 (d, J=26 Hz, H), 6.84 (d, J=13 Hz, 1H), 2.50 (m, 1H), 2.17 (m, 1H), 1.30 (m, 1H).	23
Example 6	4-(<i>trans</i> -2-hydroxymethyl-cyclopropyl)imidazole trifluoroacetic acid salt	δ 8.50 (s, 1H), 7.15 (s, 1H), 3.65 (m, 1H), 3.55 (m, 1H), 1.90 (m, 1H), 1.51 (m, 1H), 1.10 (m, 2H).	263
Example 7	4-(<i>trans</i> -2- <i>N</i> -methylamidino-cyclopropyl)imidazole di-hydrochloric acid salt	δ 8.84 (s, 1H), 7.55 (m, 1H), 2.86 (s, 3H), 2.75 (m, 1H), 2.33 (m, 1H), 1.87 (m, 1H), 1.75 (m, 1H).	114

All references cited are hereby incorporated by reference.

WO 02/13821

PCT/US01/41738

31

The present invention is illustrated by way of the foregoing description and examples. The foregoing description is intended as a non-limiting illustration, since many variations will become apparent to those skilled in the art in view thereof. It is intended that all such variations within the scope and spirit
5 of the appended claims be embraced thereby.

Changes can be made in the composition, operation and arrangement of the method of the present invention described herein without departing from the concept and scope of the invention as defined in the following claims:

WO 02/13821


PCT/US01/41738

32

Claims

We claim:

- 5 1. A compound of the structure



wherein n is an integer of zero to six;

p is an integer of zero to two;

q is an integer of zero to four;

- 10 T is selected from the group consisting of $-NR^6R^7$, $-N(R^8)C(NR^9)R^{10}$,
 $-CN$, $-OH$, $-H$, $-OR^{11}$, $-OC(O)R^{12}$, $-C(O)R^{13}$, $-C(O)NH_2$, $-C(N-$
 $OH)H$, $-SC(S)R^{14}$, $-NR^{15}C(S)R^{16}$, $-NR^{17}C(O)R^{18}$, $-SC(NR^{19})R^{20}$,
 $-OC(NR^{21})R^{22}$, R^{23} , $-N(R^{24})C(O)N(R^{25})$, $-N(R^{26})C(O)$, and
 $-O(O)NR^{27}R^{28}$;

- 15 R^1 is selected from the group consisting of hydrogen, hydroxyl, alkyl,
 alkenyl, alkynyl, alkoxy, alkenoxy, alkynoxy, thioalkoxy,
 hydroxyalkyl, aliphatic acyl, $-CF_3$, $-N(C_1-C_3 \text{ alkyl})-C(O)(C_1-C_3$
 alkyl), $-NHC(O)NH(C_1-C_3 \text{ alkyl})$,
 $-NHC(O)N(C_1-C_3 \text{ alkyl})C(O)NH(C_1-C_3 \text{ alkyl})$, $-C_1-C_3 \text{ alkylamino}$,
 20 alkenylamino, alkynylamino, di($C_1-C_3 \text{ alkyl}$)amino,
 $-C(O)O-(C_1-C_3 \text{ alkyl})$, $-C(O)NH-(C_1-C_3 \text{ alkyl})$, $-CH=NOH$,
 $-PO_3H_2$, $-OPO_3H_2$, $-C(O)N(C_1-C_3 \text{ alkyl})_2$, haloalkyl, alkoxyalkoxy,
 carboxaldehyde, carboxamide, cycloalkyl, cycloalkenyl,
 cycloalkynyl, cycloalkylalkyl, aryl, aroyl, aryloxy, arylamino,
 25 biaryl, thioaryl, diarylamino, heterocyclyl, alkylaryl,

WO 02/13821

PCT/US01/41738

33

aralkenyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, sulfonyl, -
 SO₂-(C₁-C₃ alkyl), -SO₃-(C₁-C₃ alkyl), sulfonamido, aryloxyalkyl,
 carboxyl, carbamate and -C(O)NH(benzyl); and
 5 R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹,
 R²⁰, R²¹, R²², R²³, R²⁴, R²⁵, R²⁶, R²⁷ and R²⁸ are each independently
 selected from the group consisting of hydrogen, halogen,
 hydroxyl, alkyl, alkenyl, alkynyl, alkoxy, alkenoxy, alkynoxy,
 thioalkoxy, hydroxyalkyl, aliphatic acyl, -CF₃, -NO₂, amino, -CN,
 carboxy, -N(C₁-C₃ alkyl)-C(O)(C₁-C₃ alkyl), -NHC(O)NH(C₁-C₃
 10 alkyl), -NHC(O)N(C₁-C₃ alkyl)C(O)NH(C₁-C₃ alkyl), -C₁-C₃
 alkylamino, alkenylamino, alkynylamino, di(C₁-C₃ alkyl)amino, -
 C(O)O-(C₁-C₃ alkyl), -C(O)NH-(C₁-C₃ alkyl), -CH=NOH, -PO₃H₂,
 -OPO₃H₂, -C(O)N(C₁-C₃ alkyl)₂, haloalkyl, alkoxyalkoxy,
 carboxaldehyde, carboxamide, cycloalkyl, cycloalkenyl,
 15 cycloalkynyl, cycloalkylalkyl, aryl, aroyl, aryloxy, arylamino,
 biaryl, thioaryl, diarylamino, heterocyclyl, alkylaryl, aralkenyl,
 aralkyl, alkylheterocyclyl, heterocyclylalkyl, sulfonyl, -SO₂-(C₁-
 C₃ alkyl), -SO₃-(C₁-C₃ alkyl), sulfonamido, aryloxyalkyl,
 carboxyl, carbamate and -C(O)NH(benzyl);
 20 wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴,
 R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²⁰, R²¹, R²², R²³, R²⁴, R²⁵, R²⁶, R²⁷
 and R²⁸ are unsubstituted or substituted with at least one
 electron donating or electron withdrawing group;
 and pharmaceutically acceptable salts thereof;
 25 with the proviso that when T is -NR⁶R⁷, R¹ is hydrogen and n is zero, R⁶
 and R⁷ are not both hydrogen;
 and the proviso that when T is -OH, n is one, R⁴ and R⁵ are each
 hydrogen, and p and q are zero, R¹ is not triphenylmethyl;
 and the proviso that when T is -C(O)R¹³ and n is zero, R¹³ is not
 30 hydrogen or a chiral moiety.

WO 02/13821

PCT/US01/41738

34


2. The compound of claim 1 wherein
 n is an integer of zero to three;
 R¹ is hydrogen;
 R², R³, R⁴ and R⁵ are each independently selected from the group
 consisting of hydrogen, halogen, hydroxyl, lower alkyl, alkenyl,
 alkynyl and aryl; and
 R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²⁰, R²¹, R²²
 and R²³ are each independently selected from the group consisting
 of hydrogen, lower alkyl, alkenyl, alkynyl, aryl and heterocyclyl.

3. The compound of claim 2 wherein n is zero and
 T is selected from the group consisting of -N(R⁸)C(NR⁹)R¹⁰,
 -OC(O)R¹², -C(O)R¹³, -C(O)NH₂, -C(N-OH)H, -SC(S)R¹⁴,
 -NR¹⁵C(S)R¹⁶, -NR¹⁷C(O)R¹⁸, -SC(NR¹⁹)R²⁰ and -OC(NR²¹)R²².

4. The compound of claim 2 wherein n is one and
 T is selected from the group consisting of -NR⁶R⁷,
 -CN, -OH, -H, -OR¹¹ and R²³.

5. The compound of claim 1 further comprising derivatives of said
 compound selected from the group consisting of esters, carbamates,
 amins, amides, optical isomers and pro-drugs thereof.

6. The compound of claim 1 of the structure



wherein n is an integer of zero to three;

WO 02/13821

PCT/US01/41738

35

T is selected from the group consisting of $-NR^6R^7$, $-N(R^8)C(NR^9)R^{10}$,
 $-CN$, $-OH$, $-H$, $-OR^{11}$, $-OC(O)R^{12}$, $-C(O)R^{13}$, $-C(O)NH_2$, $-C(N-$
 $OH)H$, $-SC(S)R^{14}$, $-NR^{15}C(S)R^{16}$, $-NR^{17}C(O)R^{18}$, $-SC(NR^{19})R^{20}$,
 $-OC(NR^{21})R^{22}$ and R^{23} ;

- 5 R^1 is selected from the group consisting of hydrogen, hydroxyl, alkyl,
 alkenyl, alkynyl, alkoxy, alkenoxy, alkynoxy, thioalkoxy,
 hydroxyalkyl, aliphatic acyl, $-CF_3$, $-N(C_1-C_3 \text{ alkyl})-C(O)(C_1-C_3$
 $alkyl)$, $-NHC(O)NH(C_1-C_3 \text{ alkyl})$,
 $-NHC(O)N(C_1-C_3 \text{ alkyl})C(O)NH(C_1-C_3 \text{ alkyl})$, $-C_1-C_3$ alkylamino,
 10 alkenylamino, alkynylamino, $di(C_1-C_3 \text{ alkyl})amino$,
 $-C(O)O-(C_1-C_3 \text{ alkyl})$, $-C(O)NH-(C_1-C_3 \text{ alkyl})$, $-CH=NOH$,
 $-PO_3H_2$, $-OPO_3H_2$, $-C(O)N(C_1-C_3 \text{ alkyl})_2$, haloalkyl, alkoxyalkoxy,
 carboxaldehyde, carboxamide, cycloalkyl, cycloalkenyl,
 15 cycloalkynyl, cycloalkylalkyl, aryl, aroyl, aryloxy, arylamino,
 biaryl, thioaryl, diarylamino, heterocyclyl, alkylaryl,
 aralkenyl, aralkyl, alkylheterocyclyl, heterocyclylalkyl, sulfonyl,
 $-SO_2-(C_1-C_3 \text{ alkyl})$, $-SO_3-(C_1-C_3 \text{ alkyl})$, sulfonamido,
 aryloxyalkyl, carboxyl, carbamate and $-C(O)NH(benzyl)$; and
 $R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20},$
 20 R^{21}, R^{22} and R^{23} are each independently selected from the group
 consisting of hydrogen, halogen, hydroxyl, alkyl, alkenyl,
 alkynyl, alkoxy, alkenoxy, alkynoxy, thioalkoxy, hydroxyalkyl,
 aliphatic acyl, $-CF_3$, $-NO_2$, amino, $-CN$, carboxy, $-N(C_1-C_3 \text{ alkyl})-$
 $C(O)(C_1-C_3 \text{ alkyl})$, $-NHC(O)NH(C_1-C_3 \text{ alkyl})$,
 25 $-NHC(O)N(C_1-C_3 \text{ alkyl})C(O)NH(C_1-C_3 \text{ alkyl})$, $-C_1-C_3$ alkylamino,
 alkenylamino, alkynylamino, $di(C_1-C_3 \text{ alkyl})amino$, $-C(O)O-(C_1-$
 $C_3 \text{ alkyl})$, $-C(O)NH-(C_1-C_3 \text{ alkyl})$, $-CH=NOH$, $-PO_3H_2$, $-OPO_3H_2$,
 $-C(O)N(C_1-C_3 \text{ alkyl})_2$, haloalkyl, alkoxyalkoxy, carboxaldehyde,
 carboxamide, cycloalkyl, cycloalkenyl, cycloalkynyl,
 30 cycloalkylalkyl, aryl, aroyl, aryloxy, arylamino, biaryl, thioaryl,
 diarylamino, heterocyclyl, alkylaryl, aralkenyl, aralkyl,
 alkylheterocyclyl, heterocyclylalkyl, sulfonyl, $-SO_2-(C_1-C_3 \text{ alkyl})$,

WO 02/13821

PCT/US01/41738

36

-SO₃-(C₁-C₃ alkyl), sulfonamido, aryloxyalkyl, carboxyl, carbamate and -C(O)NH(benzyl);

wherein R¹, R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²⁰, R²¹, R²² and R²³ are unsubstituted or substituted with at least one electron donating or electron withdrawing group;

and pharmaceutically acceptable salts thereof;

with the proviso that when T is -NR⁶R⁷, R¹ is hydrogen and n is zero, R⁶ and R⁷ are not both hydrogen;

and the proviso that when T is -OH, n is one, and R⁴ and R⁵ are each hydrogen, R¹ is not triphenylmethyl;

and the proviso that when T is -C(O)R¹³ and n is zero, R¹³ is not hydrogen or a chiral moiety.


7. The compound of claim 6 wherein
R¹ is hydrogen;
R³ is selected from the group consisting of hydrogen and lower alkyl;
R⁴ and R⁵ are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, lower alkyl, alkenyl, alkynyl and aryl; and
R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²⁰, R²¹, R²² and R²³ are each independently selected from the group consisting of hydrogen, lower alkyl, alkenyl, alkynyl, aryl and heterocyclyl.

8. A compound of the structure

WO 02/13821

PCT/US01/41738

37



wherein T is selected from the group consisting of $-N(R^8)C(NR^9)R^{10}$,
 $-OC(O)R^{12}$, $-C(O)R^{13}$, $-C(O)NH_2$, $-C(N-OH)H$, $-SC(S)R^{14}$,
 $-NR^{15}C(S)R^{16}$, $-NR^{17}C(O)R^{18}$, $-SC(NR^{19})R^{20}$ and $-OC(NR^{21})R^{22}$;

5 R^3 is selected from the group consisting of hydrogen and lower alkyl;

and,


$R^8, R^9, R^{10}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}$ and R^{22} are each
independently selected from the group consisting of hydrogen,
lower alkyl, alkenyl, alkynyl, aryl and heterocyclyl;

10 wherein $R^3, R^8, R^9, R^{10}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}$,
 R^{21} and R^{22} are unsubstituted or substituted with at least
one electron donating or electron withdrawing group;

and pharmaceutically acceptable salts thereof;

15 with the proviso that when T is $-C(O)R^{13}$, R^{13} is not
hydrogen or a chiral moiety.

9. A compound of the structure



wherein T is selected from the group consisting of $-NR^6R^7$,
 $-CN$, $-OH$, $-H$, $-OR^{11}$ and R^{23} ;

20

R^3 is selected from the group consisting of hydrogen and methyl;

WO 02/13821

PCT/US01/41738

38

- R^4 and R^5 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, lower alkyl, alkenyl, alkynyl and aryl; and,
 R^6 , R^7 , R^{11} and R^{23} are each independently selected from the group consisting of hydrogen, lower alkyl, alkenyl, alkynyl, aryl and heterocyclyl;
wherein R^3 , R^4 , R^5 , R^6 , R^7 , R^{11} and R^{23} are unsubstituted or substituted with at least one electron donating or electron withdrawing group;
and pharmaceutically acceptable salts thereof.
10. The compound of claim 6 further comprising derivatives of said compound selected from the group consisting of esters, carbamates, amins, amides, optical isomers and pro-drugs thereof.
11. The compound of claim 1 selected from the group consisting of 4-(*trans*-2-cyano-cyclopropyl) imidazole, 4-(*trans*-2-aminocarbonyl-cyclopropyl) imidazole, 4-(*trans*-2-amidino-cyclopropyl) imidazole, 4-(*trans*-2-aminomethyl-cyclopropyl) imidazole, 4-(*trans*-2-*N*-hydroxyimino-cyclopropyl) imidazole, 4-(*trans*-2-hydroxymethyl-cyclopropyl) imidazole, 4-(*trans*-2-*N*-methylamidino-cyclopropyl) imidazole, 4-(*trans*-2-aminomethyl-2-methyl-cyclopropyl) imidazole, 4-(*trans*-2-amidino-2-methyl-cyclopropyl) imidazole and pharmaceutically acceptable salts thereof.
12. The compound of claim 11 further comprising derivatives of said compound selected from the group consisting of esters, carbamates, amins, amides, optical isomers and pro-drugs thereof.
13. A pharmaceutical composition comprising:
a compound of claim 1
in a pharmaceutically acceptable carrier.

WO 02/13821

PCT/US01/41738

39

14 . A method for regulation of histamine H₃ receptors in a mammal by agonism, antagonism, or inverse agonism of said receptors, comprising administering to a mammal in need of such regulation a therapeutic amount of a compound of claim 1.

5

15. A method of treating allergy, cardiovascular disease, inflammation, hypotension, glaucoma, sleeping disorders, states of hyper- and hypo-motility of the gastro-intestinal tract, hypo- and hyper-activity of the central nervous system, Alzheimer's, schizophrenia, obesity and migraines comprising administering to a mammal in need of such treatment a therapeutic amount of a compound of claim 1.

10

15

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/41738

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : A61K 31/4164; C07D 233/64 US CL : 514/400; 548/345.1, 335.5, 336.1, 336.5, 338.1, 341.1 According to International Patent Classification (IPC) or to both national classification and IPC																				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 514/400; 548/345.1, 335.5, 336.1, 336.5, 338.1, 341.1 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) STN CAS ONLINE																				
C. DOCUMENTS CONSIDERED TO BE RELEVANT																				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																		
X	SCHUBERT, HERMAN, 'Synthesis and properties of alicyclic substituted imidazoles. II.', Chem. abstr., Volume 58, Number 5, 04 March 1963 (Columbus.OH, USA), column 2, the abstract No. 4542c, J. Prakt. Chem. 1962, 18(3-4), 199-206 (Ger), especially CA Registry Number 89830-98-8.	1, 2, 4, 6, 7, 9																		
X	US 6,008,240 A (PHILLIPS ET AL.) 28 December 1999 (28/12/99), see entire document, especially columns 13 and 14.	1-15																		
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																				
<table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>"T"</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td>"X"</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"E" earlier document published on or after the international filing date</td> <td>"Y"</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"A"</td> <td>document member of the same patent family</td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td></td> <td></td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"A"	document member of the same patent family	"O" document referring to an oral disclosure, use, exhibition or other means			"P" document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																		
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																		
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																		
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"A"	document member of the same patent family																		
"O" document referring to an oral disclosure, use, exhibition or other means																				
"P" document published prior to the international filing date but later than the priority date claimed																				
Date of the actual completion of the international search 26 SEPTEMBER 2001		Date of mailing of the international search report 25 OCT 2001																		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer LAURA L. STOCKTON <i>Laura L. Stockton</i> Telephone No. (703) 305-1235																		

This Page is inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images
problems checked, please do not report the
problems to the IFW Image Problem Mailbox**